Back to Search Start Over

Bioprospecting of Sea Anemones (Cnidaria, Anthozoa, Actiniaria) for β-Defensin-like α-Amylase Inhibitors

Authors :
Daria Popkova
Nadezhda Otstavnykh
Oksana Sintsova
Sergey Baldaev
Rimma Kalina
Irina Gladkikh
Marina Isaeva
Elena Leychenko
Source :
Biomedicines, Vol 11, Iss 10, p 2682 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Diabetes mellitus is one of the most serious diseases of our century. The drugs used are limited or have serious side effects. The search for new sources of compounds for effective treatment is relevant. Magnificamide, a peptide inhibitor of mammalian α-amylases, isolated from the venom of sea anemone Heteractis magnifica, can be used for the control of postprandial hyperglycemia in diabetes mellitus. Using the RACE approach, seven isoforms of magnificamide were detected in H. magnifica tentacles. The exon–intron structure of magnificamide genes was first established, and intron retention in the mature peptide-encoding region was revealed. Additionally, an α-amylase inhibitory domain was discovered in the mucins of some sea anemones. According to phylogenetics, sea anemones diverge into two groups depending on the presence of β-defensin-like α-amylase inhibitors and/or mucin-inhibitory domains. It is assumed that the intron retention phenomenon leads to additional diversity in the isoforms of inhibitors and allows for its neofunctionalization in sea anemone tentacles. Bioprospecting of sea anemones of the order Actiniaria for β-defensin-like α-amylase inhibitors revealed a diversity of inhibitory sequences that represents a starting point for the design of effective glucose-lowering drugs.

Details

Language :
English
ISSN :
22279059
Volume :
11
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Biomedicines
Publication Type :
Academic Journal
Accession number :
edsdoj.08bd79ea261445b8cf2681916c1d8f2
Document Type :
article
Full Text :
https://doi.org/10.3390/biomedicines11102682